Nkarta Inc
Research Nkarta Inc (NKTX) on Bullrun: market cap USD 194.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNKTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 194.10M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 99.93M
- Free cash flow-USD 28.61M
Valuation Snapshot
latest market cap is USD 194.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 104.08M | -USD 89.91M | n/a | -1.41 | USD 39.63M | USD 76.42M | USD 312.33M |
| FY2024 | USD 0 | -USD 108.79M | -USD 104.11M | n/a | -1.6 | USD 27.87M | USD 80.27M | USD 407.98M |
| FY2023 | n/a | -USD 117.50M | -USD 114.31M | n/a | -2.4 | USD 31.04M | USD 88.34M | USD 273.29M |
| FY2022 | n/a | -USD 113.84M | -USD 104.11M | n/a | -2.61 | USD 37.49M | USD 72.48M | USD 372.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 194.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 131.50M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 175.91M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 323.88M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 292.39M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 506.11M | n/a | n/a | n/a |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nkarta Inc's market cap?
Nkarta Inc's market capitalization is USD 194.10M.
What does Nkarta Inc do?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.